Dec 6, 2018
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
Multiple Myeloma Research Consortium MyDRUG RRMM NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG) Multiple...
362
Dec 6, 2018
RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma
RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation...
257
Dec 3, 2018
NCT03720041: Phase 3 Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Elig. New MM (FiTNEss)
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss) FiTNEss (UK-MRA...
352
Dec 15, 2017
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma -TNE
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant A...
66
Dec 15, 2017
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma A Safety, PK and Efficacy Study of...
276
Dec 7, 2017
NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second ASCT RRMM
Multiple Myeloma Research Consortium NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous...
79
Dec 6, 2017
NCT03188172: Phase 2 - MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)
MUKnineb Study OPTIMUM To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab...
545
Dec 5, 2017
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM
KarMMa bb2121 NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma...
544
Dec 16, 2016
NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
CC-220-MM-001 NDMM Newly Diagnosed Multiple Myeloma RRMM Relapsed Refractory Multiple Myeloma A Study to Determine Dose, Safety,...
446
Dec 9, 2016
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401
CRB-401 NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma Study CRB-401...
439
Dec 9, 2016
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Trial of...
84
Dec 9, 2016
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM A Study of PVX-410, a Cancer...
197
Dec 8, 2016
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
ELOQUENT-3 trial NCT02654132: Phase 2: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without...
307
Dec 3, 2016
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 This is a...
177
Dec 19, 2015
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
GEM-CESAR trial PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...
464
Dec 3, 2015
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
GEM14 Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM Trial Studying...
270
Dec 13, 2014
NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency
NCT02045017: Phase 2: Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency Efficacy and Safety...
103
Dec 11, 2014
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma E-PRISM: Phase...
142
Dec 7, 2013
NCT01946477: Phase 2 -Pomalidomide Combination With Low-dose Dex +/- Dara in RRMM Myeloma POM MM 014
POM MM 014 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and...
65